Quantitative analysis of caveolin-rich lipid raft proteins from primary and metastatic colorectal cancer clones

Journal of Proteomics

Volumn 75, Issue 9, 2012, Pages 2629-2637

  Arielly, Shirley S ^a   Ariel, Matty ^a   Yehuda, Rivka ^a   Scigelova, Michaela ^b   Yehezkel, Galit ^a   Khalaila, Isam ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

Cancer; Caveolin; Lipid rafts; Metastasis; Proteins; Quantification

Indexed keywords

CAVEOLIN; TUMOR MARKER;

ARTICLE; CARCINOGENESIS; CELL ADHESION; COLORECTAL CANCER; CONTROLLED STUDY; FOCAL ADHESION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOBLOTTING; MASS SPECTROMETRY; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; VALIDATION PROCESS;

CARRIER PROTEINS; CAVEOLIN 1; CAVEOLINS; CELL ADHESION; CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; COLORECTAL NEOPLASMS; HUMANS; MEMBRANE MICRODOMAINS; MITOCHONDRIAL PROTEINS; NEOPLASM METASTASIS; PROTEOMICS; TANDEM MASS SPECTROMETRY; TUMOR CELLS, CULTURED;

EID: 84860472136     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.03.011     Document Type: Article

References (44)

1. Brown D.A. Lipid rafts, detergent-resistant membranes, and raft targeting signals. Physiol (Bethesda) 2006, 21:430-439.
2. Simons K., Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000, 1:31-39.
3. Carver L.A., Schnitzer J.E. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 2003, 3:571-581.
4. Parton R.G. Caveolae and caveolins. Curr Opin Cell Biol 1996, 8:542-548.
5. Schnitzer J.E., Oh P., Pinney E., Allard J. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J Cell Biol 1994, 127:1217-1232.
6. Smart E.J., Graf G.A., McNiven M.A., Sessa W.C., Engelman J.A., Scherer P.E., et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 1999, 19:7289-7304.
7. Le Roy C., Wrana J.L. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 2005, 6:112-126.
8. Torres V.A., Tapia J.C., Rodriguez D.A., Parraga M., Lisboa P., Montoya M., et al. Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin. J Cell Sci 2006, 119:1812-1823.
9. Fine S.W., Lisanti M.P., Galbiati F., Li M. Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol 2001, 115:719-724.
10. Yang G., Truong L.D., Timme T.L., Ren C., Wheeler T.M., Park S.H., et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998, 4:1873-1880.
11. Carver L.A., Schnitzer J.E., Anderson R.G., Mohla S. Role of caveolae and lipid rafts in cancer: workshop summary and future needs. Cancer Res 2003, 63:6571-6574.
12. Foster L.J., De Hoog C.L., Mann M. Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc Natl Acad Sci U S A 2003, 100:5813-5818.
13. Song K.S., Li S., Okamoto T., Quilliam L.A., Sargiacomo M., Lisanti M.P. Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem 1996, 271:9690-9697.
14. Johnston M.D., Finter N.B., Young P.A. Dye uptake method for assay of interferon activity. Methods Enzymol 1981, 78:394-399.
15. Bradford M.M. Rapid and sensitive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
16. Rappsilber J., Mann M., Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc 2007, 2:1896-1906.
17. Brun R., Rademakers F. ROOT - an object oriented data analysis framework. Nucl Instrum Meth Phys Res 1996, 389:81-86.
18. Hewitt R.E., McMarlin A., Kleiner D., Wersto R., Martin P., Tsokos M., et al. Validation of a model of colon cancer progression. J Pathol 2000, 192:446-454.
19. Duranton B., Holl V., Schneider Y., Carnesecchi S., Gosse F., Raul F., et al. Polyamine metabolism in primary human colon adenocarcinoma cells (SW480) and their lymph node metastatic derivatives (SW620). Amino Acids (Vienna) 2003, 24:63-72.
20. Provenzani A., Fronza R., Loreni F., Pascale A., Amadio M., Quattrone A. Global alterations in mRNA polysomal recruitment in a cell model of colorectal cancer progression to metastasis. Carcinogenesis (Oxf) 2006, 27:1323-1333.
21. Zhao L., Liu L., Wang S., Zhang Y.F., Yu L., Ding Y.Q. Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. J Cancer Res Clin Oncol 2007, 133:771-782.
22. Chen J.S., Chen K.T., Fan C.W., Han C.L., Chen Y.J., Yu J.S., et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBS J 2010, 277:3028-3038.
23. Warburg O., Wind F., Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927, 8:519-530.
24. Dixon W.T., Sikora L.K., Demetrick D.J., Jerry L.M. Isolation and characterization of a heterodimeric surface antigen on human melanoma cells and evidence that it is the 4F2 cell activation/proliferation molecule. Int J Cancer 1990, 45:59-68.
25. Dodelet V.C., Pasquale E.B. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 2000, 19:5614-5619.
26. Duncan R., Carpenter B., Main L.C., Telfer C., Murray G.I. Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 2008, 98:426-433.
27. Gastl G., Spizzo G., Obrist P., Dunser M., Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000, 356:1981-1982.
28. Gong J., Wang D., Sun L., Zborowska E., Willson J.K., Brattain M.G. Role of alpha 5 beta 1 integrin in determining malignant properties of colon carcinoma cells. Cell Growth Differ 1997, 8:83-90.
29. Hegde P., Qi R., Gaspard R., Abernathy K., Dharap S., Earle-Hughes J., et al. Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. Cancer Res 2001, 61:7792-7797.
30. Kanekura T., Chen X., Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 2002, 99:520-528.
31. Kim K.B., Kim B.W., Choo H.J., Kwon Y.C., Ahn B.Y., Choi J.S., et al. Proteome analysis of adipocyte lipid rafts reveals that gC1qR plays essential roles in adipogenesis and insulin signal transduction. Proteomics 2009, 9:2373-2382.
32. Ghosh I., Chowdhury A.R., Rajeswari M.R., Datta K. Differential expression of hyaluronic acid binding protein 1 (HABP1)/P32/C1QBP during progression of epidermal carcinoma. Mol Cell Biochem 2004, 267:133-139.
33. Rubinstein D.B., Stortchevoi A., Boosalis M., Ashfaq R., Ghebrehiwet B., Peerschke E.I., et al. Receptor for the globular heads of C1q (gC1q-R, p33, hyaluronan-binding protein) is preferentially expressed by adenocarcinoma cells. Int J Cancer 2004, 110:741-750.
34. Amamoto R., Yagi M., Song Y., Oda Y., Tsuneyoshi M., Naito S., et al. Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy. Cancer Sci 2011, 102:639-647.
35. Parle-McDermott A., McWilliam P., Tighe O., Dunican D., Croke D.T. Serial analysis of gene expression identifies putative metastasis-associated transcripts in colon tumour cell lines. Br J Cancer 2000, 83:725-728.
36. Kim K.B., Yi J.S., Nguyen N., Lee J.H., Kwon Y.C., Ahn B.Y., et al. Cell-surface receptor for complement component C1q (gC1qR) is a key regulator for lamellipodia formation and cancer metastasis. J Biol Chem 2011, 286:23093-23101.
37. von Schlippe M., Marshall J.F., Perry P., Stone M., Zhu A.J., Hart I.R. Functional interaction between E-cadherin and alphav-containing integrins in carcinoma cells. J Cell Sci 2000, 113(Pt 3):425-437.
38. Bellone G., Alloatti G., Levi R., Geuna M., Tetta C., Peruzzi L., et al. Identification of a new epitope of the 4F2/44D7 molecular complex present on sarcolemma and isolated cardiac fibers. Eur J Immunol 1989, 19:1-8.
39. Fenczik C.A., Sethi T., Ramos J.W., Hughes P.E., Ginsberg M.H. Complementation of dominant suppression implicates CD98 in integrin activation. Nature 1997, 390:81-85.
40. Rintoul R.C., Buttery R.C., Mackinnon A.C., Wong W.S., Mosher D., Haslett C., et al. Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth. Mol Biol Cell 2002, 13:2841-2852.
41. Esteban F., Ruiz-Cabello F., Concha A., Perez Ayala M., Delgado M., Garrido F. Relationship of 4F2 antigen with local growth and metastatic potential of squamous cell carcinoma of the larynx. Cancer 1990, 66:1493-1498.
42. Chin D., Boyle G.M., Williams R.M., Ferguson K., Pandeya N., Pedley J., et al. Novel markers for poor prognosis in head and neck cancer. Int J Cancer 2005, 113:789-797.
43. Brown R.S., Wahl R.L. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993, 72:2979-2985.
44. Vosseller K., Wells L., Lane M.D., Hart G.W. Elevatednucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 2002, 99:5313-5318.